tradingkey.logo

LENSAR Inc

LNSR
查看详细走势图
12.045USD
+0.035+0.29%
交易中 美东报价延迟15分钟
143.76M总市值
亏损市盈率 TTM

LENSAR Inc

12.045
+0.035+0.29%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.29%

5天

+4.65%

1月

+22.53%

6月

-2.94%

今年开始到现在

+34.73%

1年

+56.43%

查看详细走势图

TradingKey LENSAR Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

LENSAR Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名104/208位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价15.00。中期看,股价处于平稳状态。近一个月,市场表现很强,技术面和基本面综合得分较高,很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

LENSAR Inc评分

相关信息

行业排名
104 / 208
全市场排名
236 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 2 位分析师
持有
评级
15.000
目标均价
+34.05%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

LENSAR Inc亮点

亮点风险
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
业绩高增长
公司营业收入稳步增长,连续3年增长51.29%
业绩增长期
公司处于发展阶段,最新年度总收入53.49M美元
利润高增长
公司净利润处于行业前列,最新年度总收入53.49M美元
估值合理
公司最新PE估值-2.75,处于3年历史合理位
机构减仓
最新机构持股5.64M股,环比减少1.71%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值507.60K
活跃度降低
近期活跃度降低,过去20天平均换手率-0.07

LENSAR Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

LENSAR Inc简介

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
公司代码LNSR
公司LENSAR Inc
CEOCurtis (Nicholas T)
网址https://www.lensar.com/

常见问题

LENSAR Inc(LNSR)的当前股价是多少?

LENSAR Inc(LNSR)的当前股价是 12.045。

LENSAR Inc的股票代码是什么?

LENSAR Inc的股票代码是LNSR。

LENSAR Inc股票的52周最高点是多少?

LENSAR Inc股票的52周最高点是17.310。

LENSAR Inc股票的52周最低点是多少?

LENSAR Inc股票的52周最低点是7.250。

LENSAR Inc的市值是多少?

LENSAR Inc的市值是143.76M。

LENSAR Inc的净利润是多少?

LENSAR Inc的净利润为-31.40M。

现在LENSAR Inc(LNSR)的股票是买入、持有还是卖出?

根据分析师评级,LENSAR Inc(LNSR)的总体评级为持有,目标价格为15.000。

LENSAR Inc(LNSR)股票的每股收益(EPS TTM)是多少

LENSAR Inc(LNSR)股票的每股收益(EPS TTM)是-4.374。
KeyAI